NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) (the “Company”), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that it is offering to sell up to $150 million principal amount of its convertible senior notes due 2019 (the “notes”) through a private offering. The Company expects to grant the initial purchasers of the notes an option to purchase, within a 13-day period beginning on and including the first date of the original issuance of the notes, up to an additional $22.5 million principal amount of notes, solely to cover over-allotments.
Help employers find you! Check out all the jobs and post your resume.
